Calcification artery calcium (CAC) scoring is a valuable tool for determining the risk of major adverse cardiac events. It was found that CAC can be quantitatively assessed, by manual scoring or using deep-learning, on low-dose non electrocardiogram-gated, contrast-enhanced or non-enhanced computed tomography (CT-scan) performed in association of PET acquisition, with a good agreement with standard scans. The purpose of this study is to determine the impact of a systematic coronary artery calcification evaluation in patients undergoing flourine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) imaging to improve primary prevention of cardiovascular diseases. A visual calcification artery calcium assessment will be made for each patient, dividing them into four groups: none, mild, moderate or heavy calcification artery calcium. When possible, a calcification artery calcium score will be computed. Each patient will complete a questionnaire to collect risk factors, history of cardiovascular diseases and medications.
Study Type
OBSERVATIONAL
Enrollment
200
Self-administered questionnaire to assess the participants risk factors, history of heart disease and medications.
Centre Hospitalier Universitaire d'Orléans
Orléans, France
Prevalence of moderate calcification artery calcium (CAC) in participants without history of cardiac disease
In participants who had neither history of cardiac disease nor cardiology follow-up, the proportion of those with at least moderate CAC
Time frame: Baseline
Prevalence of coronary heart disease among participants
Proportion of participants with history of coronary heart disease, according to questionnaire data
Time frame: Baseline
Correlation of CAC with the medical indication for PET imaging
Dividing participants into subgroups according to PET indication, determine in which subgroup the proportion of participants with at least moderate CAC is the highest
Time frame: Baseline
Prevalence of CAC in young participants (< 45 years old)
Proportion of young participants with at least mild CAC
Time frame: Baseline
Prevalence of moderate CAC in participants not taking low-cholesterol drug
In participants not taking low-cholesterol drug, proportion of them with at least moderate CAC
Time frame: Baseline
Prevalence of no CAC in participants taking statins
In participants taking statins, proportion of them without CAC
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.